DSG's EDC to be Used by Biotech Co. for Chronic Kidney Disease
MALVERN, Pa., Jan. 29, 2010 —DSG‘s eCaseLink™ Electronic Data Capture (EDC) and data management are currently being used by a biotechnology company for two current Phase II and Phase IIa clinical trials for treatments of progressive and chronic kidney disease. The company uses DSG’s eCaseLink™ to automate and manage the data collection process during the clinical trial lifecycle. In addition, DSG combines data management services with eCaseLink™ to seamlessly optimize data collection and analysis.
The Phase II study, is a new treatment that may help people in the early stage of diabetic nephropathy, a progressive kidney disease. The second study, currently in Phase IIa, is a treatment for anemia in chronic kidney disease. The two clinical trials demand a data capture and management solution that speeds time-to-market while complying with all appropriate regulatory procedures. “Partnering with innovative drug companies like this, helping to find ways to help those suffering from progressive and chronic kidney disease, is an ideal way for DSG’s unique eCaseLink™ EDC system to be employed in clinical trials,” said Tony Varano, CEO of DSG.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
